Literature DB >> 31072717

Arthroscopic Surgery for Femoroacetabular Impingement in Skeletally Immature Athletes: Radiographic and Clinical Analysis.

Christopher M Larson1, Rebecca Stone McGaver2, Nicole R Collette2, M Russell Giveans2, James R Ross3, Asheesh Bedi4, Jeffrey J Nepple5.   

Abstract

PURPOSE: To evaluate radiographic and clinical outcomes after arthroscopic femoroacetabular impingement (FAI) correction in symptomatic adolescent athletes with open physes.
METHODS: We retrospectively reviewed radiographic and clinical outcomes in patients treated with a non-physeal-sparing arthroscopic approach for symptomatic FAI with open physes and a minimum 1-year follow-up. Specific plain radiographic and computed tomography parameters were determined, and preoperative and postoperative outcomes were prospectively evaluated with modified Harris Hip Score (mHHS), 12-Item Veterans-Rand, and pain on a visual analog scale.
RESULTS: Thirty-seven hips (28 patients; 75% male) with a mean age of 15.9 years (range, 12.8-18.3 years) had imaging studies consistent with open femoral neck and iliac crest physes. The ischial tuberosity and greater trochanteric physes were open in 95% and 54% of the hips, respectively. All patients participated in organized athletics, and 50% were in multiple sports year-round. Mean follow-up was 39.8 months post-arthroscopic FAI correction. There was a mean 27.7-point improvement in the mHHS (P < .001), a 4.8-point decrease in the visual analog scale for pain (P < .001), and a 15.2-point improvement in the 12-Item Veterans-Rand physical component (P < .001). Ninety-three percent of patients returned to their preinjury level of sports participation without limitations. Thirty (81.1%) patients demonstrated improvements in mHHS greater than the minimally clinically important difference (of mHHS 8 points). Two patients could not reach minimally clinically important difference because of a preoperative mHHS of > 92. There were no postoperative physeal growth arrests, growth disturbances, physeal instability, or avascular necrosis.
CONCLUSIONS: A non-physeal-sparing arthroscopic approach for FAI in adolescents with open physes is safe and effective with no evidence of clinically relevant complication of growth arrest-related deformity or physeal instability in patients with a minimum of 1 year (mean, 39.8 months) of follow-up after surgery. Young, highly athletic adolescent patients with larger FAI deformities demonstrated greater outcomes improvement after arthroscopy. LEVEL OF EVIDENCE: Level IV, therapeutic case series.
Copyright © 2019 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31072717     DOI: 10.1016/j.arthro.2019.01.029

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  4 in total

1.  Insurance Coverage Criteria for Femoroacetabular Impingement Surgery: Are They Responding to Improving Evidence?

Authors:  Andrew M Block; Arya Minaie; James R Ross; John C Clohisy; Jeffrey J Nepple
Journal:  Iowa Orthop J       Date:  2021

2.  There is no definite consensus on the adequate radiographic correction in arthroscopic osteochondroplasty for femoroacetabular impingement: a systematic review and meta-analysis.

Authors:  Dan Cohen; Abdullah Khan; Jeffrey Kay; David Slawaska-Eng; Mahmoud Almasri; Nicole Simunovic; Andrew Duong; Marc R Safran; Olufemi R Ayeni
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-06-26       Impact factor: 4.114

Review 3.  Controversial Issues in Arthroscopic Surgery for Femoroacetabular Impingement.

Authors:  Vikas Khanduja; Yong-Chan Ha; Kyung-Hoi Koo
Journal:  Clin Orthop Surg       Date:  2021-10-15

4.  The Association of α Angle on Disease Severity in Adolescent Femoroacetabular Impingement.

Authors:  Tyler R Youngman; K John Wagner; Benjamin Montanez; Benjamin L Johnson; Phillip L Wilson; William Z Morris; Daniel J Sucato; David A Podeszwa; Henry B Ellis
Journal:  J Pediatr Orthop       Date:  2021-02-01       Impact factor: 2.537

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.